Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Healthy donor T cell receptors expand functional neoantigen recognition beyond patient vaccination.

Science advances·2026
Same author

Improved tumor-only variant calling and mutation burden estimation with VarNet-T.

Nature communications·2026
Same author

Prompt Engineering for Eastern Cooperative Oncology Group Status Extraction: Comparing Large Language Model Techniques.

JCO clinical cancer informatics·2026
Same author

Protrec2: tissue-specific network-based missing protein recovery method.

Briefings in bioinformatics·2025
Same author

Genomic platform specific polygenic risk scores impact breast cancer risk stratification.

Communications medicine·2025
Same author

Sanzi Yangqin Decoction alleviated epithelial barrier damage in acute lung injury by mediating CD40 in alveolar macrophages to inhibit necroptosis of pulmonary epithelial cells.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2025

Related Experiment Video

Updated: Jan 8, 2026

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

17.3K

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.

Hanaé Carrié1,2,3, Ngak Leng Sim1, Pui Mun Wong1

  • 1Genome Institute of Singapore (GIS), Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore.

Nature Communications
|December 17, 2025
PubMed
Summary

Detecting cancer mutations in cell-free DNA (cfDNA) is difficult. This study created a benchmark using patient samples to assess variant callers, improving accuracy for liquid biopsy analysis.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
08:23

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Published on: September 25, 2018

13.9K

Related Experiment Videos

Last Updated: Jan 8, 2026

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

17.3K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
08:23

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

Published on: September 25, 2018

13.9K

Area of Science:

  • Genomics
  • Cancer Research
  • Bioinformatics

Background:

  • Detecting somatic mutations in cell-free DNA (cfDNA) is limited by low variant allele frequencies and DNA degradation.
  • Accurate detection of tumor-derived DNA is crucial for non-invasive cancer diagnostics and monitoring.

Purpose of the Study:

  • To develop a robust benchmarking strategy for evaluating somatic variant callers in cfDNA.
  • To assess the performance of variant callers across various circulating tumor DNA (ctDNA) levels and sequencing depths.
  • To provide guidance for selecting optimal variant calling methods for liquid biopsy applications.

Main Methods:

  • Utilized longitudinal, patient-matched cfDNA samples from colorectal and breast cancer patients.
  • Created controlled dilution series by combining samples with high and ultra-low tumor-derived DNA levels.
  • Performed deep whole-genome (150x) and exome (2,000x) sequencing to identify variants.
  • Benchmarked nine somatic variant callers and explored machine learning for caller optimization.

Main Results:

  • Defined a reference set of approximately 37,000 single nucleotide variants and 58,000 indels.
  • Clarified the detection limits of current somatic variant calling approaches in cfDNA.
  • Identified key features that enhance variant caller accuracy for cfDNA analysis.

Conclusions:

  • The developed benchmarking strategy provides a reliable resource for assessing cfDNA analysis methods.
  • The findings offer practical guidance for selecting and optimizing somatic variant callers in liquid biopsy.
  • Improved variant detection in cfDNA has significant implications for cancer diagnostics and personalized medicine.